No, all individual medical data collected through Sigma’s screening process is privacy-protected and compliant with HIPAA regulations.
Circulating Levels of Secretory Type II Phospholipase A2 Predict Coronary Events in Patients with Coronary Artery Disease
Dec 1 / 2023
Diagnostic accuracy of carotid intima media thickness by B-mode ultrasonography in coronary artery disease patients
Dec 27 / 2023
Is Carotid Intima-Media Thickness as Predictive as Other Noninvasive Techniques for the Detection of Coronary Artery Disease?
Dec 27 / 2023
Lipoprotein-Associated Phospholipase A2 and Risk of Incident Cardiovascular Disease in a Multi-Ethnic Cohort: The MultiEthnic Study of Atherosclerosis
Dec 1 / 2023
Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease
Dec 1 / 2023
Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus
Dec 1 / 2023
Frequently Asked Questions
No, we do not use insurance. We have found that an insurance reimbursement model results in higher costs which ultimately get passed on to the individuals participating in the program. Furthermore, cardiac screening may result in increased insurance costs for participants.
Some insurance companies will issue “wellness dollars” to support outsourced health initiatives. This benefit can be applied to the cost of the HeartStart program
For patient portal or test result questions, please reach out to our team by messaging through your patient portal, or contact us:
Phone: 904-474-4622
Email: support@iamsigma.com
We ask our patients to fast for at least 8 hours. However, medication should be taken as prescribed, and drinking water or black coffee is acceptable.
Yes, we offer screening to anyone who would like to participate in the program.
Yes, patients often use HSA/FSA to cover the cost of the program.